Delivery Order SPE2DB25D3008-SPE2DB25FRDCY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $11,578.87. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a non-competitive set-aside arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Lisdexamfetamine 50 mg capsules (100-count units) with a ceiling value of $1,651.64. This competitively awarded, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on August 28, 2025, with a ceiling value of $1,726.50 and a completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.9 million and extends through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Lisdexamfetamine 10 mg capsules (100-count units) with a ceiling value of $1,278.13. This competitively awarded, firm fixed-price delivery order is set to be completed by July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,883.72 for Lisdexamfetamine 30 mg capsules (100-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under the company's broader pharmaceutical supply arrangements with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lisdexamfetamine 50 mg capsules (90-count units) valued at $1,057.44. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award practices. The delivery order is due for completion by September 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $2,587.33. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order is set to complete by July 25, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100-count units) with a ceiling value of $6,184.82. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract is scheduled for ultimate completion on September 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $3,957.98 to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on September 8, 2025, with completion targeted for September 9, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the vendor's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract valued at $11,279.96. This non-competitive delivery order is expected to be completed by September 2, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRDCYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 30 mg capsules (100-count units) on September 3, 2025, with a ceiling value of $1,176.88 and ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under a larger vehicle, reflecting the company's role as a critical pharmaceutical supplier to federal military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support Defense Health Agency and other federal healthcare programs worldwide. Lisdexamfetamine, a central nervous system stimulant used to treat attention-deficit/hyperactivity disorder, represents one of many therapeutic medications the company delivers through its federal contract portfolio, which encompasses specialty pharmaceuticals, vaccines, and medical supplies across multiple treatment domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/3/25 |